Pediatr. praxi. 2023;24(4):230-234 | DOI: 10.36290/ped.2023.061

Diagnosis and management of steroid-sensitive nephrotic syndrome in children

doc. MUDr. Jakub Zieg, Ph.D.1, doc. MUDr. Sylva Skálová, Ph.D.2
1 Pediatrická klinika, 2. LF a FN v Motole, Praha
2 Dětská klinika, LF UK a FN Hradec Králové

Idiopathic steroid-sensitive nephrotic syndrome is the most common pediatric glomerulopathy. Most of the patients have favorable outcome, however 50% of children suffer from frequently relapsing course or they are steroid dependent. At present, several steroid sparing agents are available, which are administered to induce sustained remission and to prevent steroid side effects. Here, we review current knowledge in diagnostics and management of steroid-sensitive nephrotic syndrome in children.

Keywords: nephrotic syndrome, relapse, steroid-dependent nephrotic syndrome, steroid-sensitive nephrotic syndrome, steroid-sparing agent.

Accepted: August 21, 2023; Published: September 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zieg J, Skálová S. Diagnosis and management of steroid-sensitive nephrotic syndrome in children. Pediatr. praxi. 2023;24(4):230-234. doi: 10.36290/ped.2023.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61-74. Go to original source...
    2. Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatric nephrology. 2023;38(3):877-919. Go to original source... Go to PubMed...
    3. Downie ML, Gallibois C, Parekh RS, et al. Nephrotic syndrome in infants and children: pathophysiology and management. Paediatrics and international child health. 2017;37(4):248-258. Go to original source...
    4. Vivarelli M, Massella L, Ruggiero B, et al. Minimal Change Disease. Clinical journal of the American Society of Nephrology. CJASN. 2017;12(2):332-345. Go to original source...
    5. Narla D, Swiatecka-Urban A. Therapeutic Response to Corticosteroids Remains a Valid Approach to Initial Management of Children With Idiopathic Nephrotic Syndrome. Frontiers in pediatrics. 2020;8:533. Go to original source... Go to PubMed...
    6. Hama T, Nakanishi K, Shima Y, et al. Renal biopsy criterion in idiopathic nephrotic syndrome with microscopic hematuria at onset. Pediatric nephrology. 2015;30(3):445-450. Go to original source... Go to PubMed...
    7. Preston R, Stuart HM, Lennon R. Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? Pediatric nephrology. 2019;34(2):195-210. Go to original source... Go to PubMed...
    8. Zieg J, Skálová S. Dětská nefrologie do kapsy. Praha: Mladá fronta; 2019.
    9. Boyer O, Schaefer F, Haffner D, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nature reviews Nephrology. 2021;17(4):277-289. Go to original source... Go to PubMed...
    10. Webb NJA, Woolley RL, Lambe T, et al. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. Bmj. 2019;365:l1800. Go to original source... Go to PubMed...
    11. Warshaw BL, Hymes LC. Daily single-dose and daily reduced-dose prednisone therapy for children with the nephrotic syndrome. Pediatrics. 1989;83(5):694-699. Go to original source... Go to PubMed...
    12. Christian MT, Webb NJA, Mehta S, et al. Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome: The PREDNOS 2 Randomized Clinical Trial. JAMA pediatrics. 2022;176(3):236-243. Go to original source... Go to PubMed...
    13. Kemper MJ, Valentin L, van Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatric nephrology. 2018;33(10):1641-1649. Go to original source... Go to PubMed...
    14. Fujinaga S, Kaneko K, Muto T, et al. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Archives of disease in childhood. 2006;91(8):666-670. Go to original source... Go to PubMed...
    15. Ishikura K, Yoshikawa N, Nakazato H, et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clinical journal of the American Society of Nephrology: CJASN. 2012;7(10):1576-1583. Go to original source...
    16. Cammas B, Harambat J, Bertholet-Thomas A, et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011;26(1):178-184. Go to original source...
    17. Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. The Cochrane database of systematic reviews. 2020;4(4):CD002290. Go to original source...
    18. Benz MR, Ehren R, Kleinert D, et al. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome. Therapeutic drug monitoring. 2019;41(6):696-702. Go to original source... Go to PubMed...
    19. Pawinski T, Kunicki PK, Sobieszczanska-Malek M, et al. A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine. Journal of clinical pharmacy and therapeutics. 2009;34(1):89-101. Go to original source... Go to PubMed...
    20. Tullus K, Marks SD. Indications for use and safety of rituximab in childhood renal diseases. Pediatric nephrology. 2013;28(7):1001-1009. Go to original source... Go to PubMed...
    21. Parmentier C, Delbet JD, Decramer S, et al. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatric nephrology. 2020;35(3):455-462. Go to original source... Go to PubMed...
    22. Chan EY, Webb H, Yu E, et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney international. 2020;97(2):393-401. Go to original source... Go to PubMed...
    23. Vivarelli M, Colucci M, Bonanni A, et al. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatric nephrology. 2017;32(1):181-184. Go to original source... Go to PubMed...
    24. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clinical pharmacokinetics. 2002;41(11):813-851. Go to original source...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.